Opinion

Video

Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.

Current Time 0:00
Duration 3:34
Loaded: 4.60%
Stream Type LIVE
Remaining Time 3:34
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
    Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
    Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
    Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
    Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
    Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
    Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
    Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
    Chad Tang, MD: Considerations for SBRT in metastatic RCC
    Chad Tang, MD: Considerations for SBRT in metastatic RCC
    Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
    Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
    Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
    Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
    Related Content
    Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
    April 3rd 2025

    Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

    Mehmet Asim Bilen, MD Hannah Clarke
    "The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
    Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
    April 2nd 2025

    The importance of federal funding in cancer research: A call to action

    Michael S. Cookson, MD, MMHC
    "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
    FDA updates in urology: March 2025
    April 1st 2025

    FDA updates in urology: March 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from March 2025.
    Subcutaneous nivolumab under review in EU for solid tumors
    March 31st 2025

    Subcutaneous nivolumab under review in EU for solid tumors

    Hannah Clarke
    The European Commission must issue a decision on the application on or by June 2, 2025.
    Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
    March 19th 2025

    Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

    Hannah Clarke
    "The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
    FDA greenlights trial of orellanine in metastatic renal cell carcinoma
    March 18th 2025

    FDA greenlights trial of orellanine in metastatic renal cell carcinoma

    Hannah Clarke
    The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
    © 2025 MJH Life Sciences

    All rights reserved.